img

Global Anti-VEGF Drug Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-VEGF Drug Market Research Report 2024

According to Mr Accuracy reports’s new survey, global Anti-VEGF Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-VEGF Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-VEGF Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


F. Hoffmann-La Roche Ltd
Amgen Inc
Pfizer, Inc
Xbrane Biopharma AB
Allergan
Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc
Segment by Type
Avastin
Lucentis
Eylea

Segment by Application


Age-related Macular Degeneration
Macular Edema Following Retinal Vein Occlusion
Diabetic Macular Edema
Diabetic Retinopathy

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Anti-VEGF Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Anti-VEGF Drug Market Overview
1.1 Product Overview and Scope of Anti-VEGF Drug
1.2 Anti-VEGF Drug Segment by Type
1.2.1 Global Anti-VEGF Drug Market Value Comparison by Type (2024-2034)
1.2.2 Avastin
1.2.3 Lucentis
1.2.4 Eylea
1.3 Anti-VEGF Drug Segment by Application
1.3.1 Global Anti-VEGF Drug Market Value by Application: (2024-2034)
1.3.2 Age-related Macular Degeneration
1.3.3 Macular Edema Following Retinal Vein Occlusion
1.3.4 Diabetic Macular Edema
1.3.5 Diabetic Retinopathy
1.4 Global Anti-VEGF Drug Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Drug Revenue 2018-2029
1.4.2 Global Anti-VEGF Drug Sales 2018-2029
1.4.3 Global Anti-VEGF Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Anti-VEGF Drug Market Competition by Manufacturers
2.1 Global Anti-VEGF Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Anti-VEGF Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Anti-VEGF Drug Average Price by Manufacturers (2018-2024)
2.4 Global Anti-VEGF Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Anti-VEGF Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Drug, Product Type & Application
2.7 Anti-VEGF Drug Market Competitive Situation and Trends
2.7.1 Anti-VEGF Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-VEGF Drug Players Market Share by Revenue
2.7.3 Global Anti-VEGF Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-VEGF Drug Retrospective Market Scenario by Region
3.1 Global Anti-VEGF Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Anti-VEGF Drug Global Anti-VEGF Drug Sales by Region: 2018-2029
3.2.1 Global Anti-VEGF Drug Sales by Region: 2018-2024
3.2.2 Global Anti-VEGF Drug Sales by Region: 2024-2029
3.3 Global Anti-VEGF Drug Global Anti-VEGF Drug Revenue by Region: 2018-2029
3.3.1 Global Anti-VEGF Drug Revenue by Region: 2018-2024
3.3.2 Global Anti-VEGF Drug Revenue by Region: 2024-2029
3.4 North America Anti-VEGF Drug Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Anti-VEGF Drug Sales by Country (2018-2029)
3.4.3 North America Anti-VEGF Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Drug Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Anti-VEGF Drug Sales by Country (2018-2029)
3.5.3 Europe Anti-VEGF Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-VEGF Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Anti-VEGF Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Anti-VEGF Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-VEGF Drug Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Anti-VEGF Drug Sales by Country (2018-2029)
3.7.3 Latin America Anti-VEGF Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-VEGF Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Anti-VEGF Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Anti-VEGF Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Drug Sales by Type (2018-2029)
4.1.1 Global Anti-VEGF Drug Sales by Type (2018-2024)
4.1.2 Global Anti-VEGF Drug Sales by Type (2024-2029)
4.1.3 Global Anti-VEGF Drug Sales Market Share by Type (2018-2029)
4.2 Global Anti-VEGF Drug Revenue by Type (2018-2029)
4.2.1 Global Anti-VEGF Drug Revenue by Type (2018-2024)
4.2.2 Global Anti-VEGF Drug Revenue by Type (2024-2029)
4.2.3 Global Anti-VEGF Drug Revenue Market Share by Type (2018-2029)
4.3 Global Anti-VEGF Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Anti-VEGF Drug Sales by Application (2018-2029)
5.1.1 Global Anti-VEGF Drug Sales by Application (2018-2024)
5.1.2 Global Anti-VEGF Drug Sales by Application (2024-2029)
5.1.3 Global Anti-VEGF Drug Sales Market Share by Application (2018-2029)
5.2 Global Anti-VEGF Drug Revenue by Application (2018-2029)
5.2.1 Global Anti-VEGF Drug Revenue by Application (2018-2024)
5.2.2 Global Anti-VEGF Drug Revenue by Application (2024-2029)
5.2.3 Global Anti-VEGF Drug Revenue Market Share by Application (2018-2029)
5.3 Global Anti-VEGF Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche Ltd
6.1.1 F. Hoffmann-La Roche Ltd Corporation Information
6.1.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.1.3 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product Portfolio
6.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.2 Amgen Inc
6.2.1 Amgen Inc Corporation Information
6.2.2 Amgen Inc Description and Business Overview
6.2.3 Amgen Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Amgen Inc Anti-VEGF Drug Product Portfolio
6.2.5 Amgen Inc Recent Developments/Updates
6.3 Pfizer, Inc
6.3.1 Pfizer, Inc Corporation Information
6.3.2 Pfizer, Inc Description and Business Overview
6.3.3 Pfizer, Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Pfizer, Inc Anti-VEGF Drug Product Portfolio
6.3.5 Pfizer, Inc Recent Developments/Updates
6.4 Xbrane Biopharma AB
6.4.1 Xbrane Biopharma AB Corporation Information
6.4.2 Xbrane Biopharma AB Description and Business Overview
6.4.3 Xbrane Biopharma AB Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Xbrane Biopharma AB Anti-VEGF Drug Product Portfolio
6.4.5 Xbrane Biopharma AB Recent Developments/Updates
6.5 Allergan
6.5.1 Allergan Corporation Information
6.5.2 Allergan Description and Business Overview
6.5.3 Allergan Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Allergan Anti-VEGF Drug Product Portfolio
6.5.5 Allergan Recent Developments/Updates
6.6 Bayer AG
6.6.1 Bayer AG Corporation Information
6.6.2 Bayer AG Description and Business Overview
6.6.3 Bayer AG Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Bayer AG Anti-VEGF Drug Product Portfolio
6.6.5 Bayer AG Recent Developments/Updates
6.7 Regeneron Pharmaceuticals Inc.
6.6.1 Regeneron Pharmaceuticals Inc. Corporation Information
6.6.2 Regeneron Pharmaceuticals Inc. Description and Business Overview
6.6.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product Portfolio
6.7.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
6.8 Viatris Inc
6.8.1 Viatris Inc Corporation Information
6.8.2 Viatris Inc Description and Business Overview
6.8.3 Viatris Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Viatris Inc Anti-VEGF Drug Product Portfolio
6.8.5 Viatris Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Drug Industry Chain Analysis
7.2 Anti-VEGF Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Drug Production Mode & Process
7.4 Anti-VEGF Drug Sales and Marketing
7.4.1 Anti-VEGF Drug Sales Channels
7.4.2 Anti-VEGF Drug Distributors
7.5 Anti-VEGF Drug Customers
8 Anti-VEGF Drug Market Dynamics
8.1 Anti-VEGF Drug Industry Trends
8.2 Anti-VEGF Drug Market Drivers
8.3 Anti-VEGF Drug Market Challenges
8.4 Anti-VEGF Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-VEGF Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Anti-VEGF Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Anti-VEGF Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Anti-VEGF Drug Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Anti-VEGF Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Anti-VEGF Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Anti-VEGF Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Anti-VEGF Drug Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Anti-VEGF Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Anti-VEGF Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Drug, Product Type & Application
Table 12. Global Key Manufacturers of Anti-VEGF Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Anti-VEGF Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Anti-VEGF Drug Sales Market Share by Region (2018-2024)
Table 19. Global Anti-VEGF Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Anti-VEGF Drug Sales Market Share by Region (2024-2029)
Table 21. Global Anti-VEGF Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Anti-VEGF Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Anti-VEGF Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Anti-VEGF Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Anti-VEGF Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Anti-VEGF Drug Sales by Country (2018-2024) & (K Units)
Table 27. North America Anti-VEGF Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Anti-VEGF Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Anti-VEGF Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Anti-VEGF Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Anti-VEGF Drug Sales by Country (2018-2024) & (K Units)
Table 32. Europe Anti-VEGF Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Anti-VEGF Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Anti-VEGF Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Anti-VEGF Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Drug Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Anti-VEGF Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Anti-VEGF Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Anti-VEGF Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Anti-VEGF Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Anti-VEGF Drug Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Anti-VEGF Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Anti-VEGF Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Anti-VEGF Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Anti-VEGF Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Anti-VEGF Drug Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Anti-VEGF Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Anti-VEGF Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Anti-VEGF Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Anti-VEGF Drug Sales (K Units) by Type (2018-2024)
Table 51. Global Anti-VEGF Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Anti-VEGF Drug Sales Market Share by Type (2018-2024)
Table 53. Global Anti-VEGF Drug Sales Market Share by Type (2024-2029)
Table 54. Global Anti-VEGF Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Anti-VEGF Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Anti-VEGF Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Anti-VEGF Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Anti-VEGF Drug Price (US$/Unit) by Type (2018-2024)
Table 59. Global Anti-VEGF Drug Price (US$/Unit) by Type (2024-2029)
Table 60. Global Anti-VEGF Drug Sales (K Units) by Application (2018-2024)
Table 61. Global Anti-VEGF Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Anti-VEGF Drug Sales Market Share by Application (2018-2024)
Table 63. Global Anti-VEGF Drug Sales Market Share by Application (2024-2029)
Table 64. Global Anti-VEGF Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Anti-VEGF Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Anti-VEGF Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Anti-VEGF Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Anti-VEGF Drug Price (US$/Unit) by Application (2018-2024)
Table 69. Global Anti-VEGF Drug Price (US$/Unit) by Application (2024-2029)
Table 70. F. Hoffmann-La Roche Ltd Corporation Information
Table 71. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 72. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product
Table 74. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 75. Amgen Inc Corporation Information
Table 76. Amgen Inc Description and Business Overview
Table 77. Amgen Inc Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Amgen Inc Anti-VEGF Drug Product
Table 79. Amgen Inc Recent Developments/Updates
Table 80. Pfizer, Inc Corporation Information
Table 81. Pfizer, Inc Description and Business Overview
Table 82. Pfizer, Inc Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Pfizer, Inc Anti-VEGF Drug Product
Table 84. Pfizer, Inc Recent Developments/Updates
Table 85. Xbrane Biopharma AB Corporation Information
Table 86. Xbrane Biopharma AB Description and Business Overview
Table 87. Xbrane Biopharma AB Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Xbrane Biopharma AB Anti-VEGF Drug Product
Table 89. Xbrane Biopharma AB Recent Developments/Updates
Table 90. Allergan Corporation Information
Table 91. Allergan Description and Business Overview
Table 92. Allergan Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Allergan Anti-VEGF Drug Product
Table 94. Allergan Recent Developments/Updates
Table 95. Bayer AG Corporation Information
Table 96. Bayer AG Description and Business Overview
Table 97. Bayer AG Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Bayer AG Anti-VEGF Drug Product
Table 99. Bayer AG Recent Developments/Updates
Table 100. Regeneron Pharmaceuticals Inc. Corporation Information
Table 101. Regeneron Pharmaceuticals Inc. Description and Business Overview
Table 102. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product
Table 104. Regeneron Pharmaceuticals Inc. Recent Developments/Updates
Table 105. Viatris Inc Corporation Information
Table 106. Viatris Inc Description and Business Overview
Table 107. Viatris Inc Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Viatris Inc Anti-VEGF Drug Product
Table 109. Viatris Inc Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Anti-VEGF Drug Distributors List
Table 113. Anti-VEGF Drug Customers List
Table 114. Anti-VEGF Drug Market Trends
Table 115. Anti-VEGF Drug Market Drivers
Table 116. Anti-VEGF Drug Market Challenges
Table 117. Anti-VEGF Drug Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-VEGF Drug
Figure 2. Global Anti-VEGF Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Anti-VEGF Drug Market Share by Type in 2022 & 2029
Figure 4. Avastin Product Picture
Figure 5. Lucentis Product Picture
Figure 6. Eylea Product Picture
Figure 7. Global Anti-VEGF Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Anti-VEGF Drug Market Share by Application in 2022 & 2029
Figure 9. Age-related Macular Degeneration
Figure 10. Macular Edema Following Retinal Vein Occlusion
Figure 11. Diabetic Macular Edema
Figure 12. Diabetic Retinopathy
Figure 13. Global Anti-VEGF Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Anti-VEGF Drug Market Size (2018-2029) & (US$ Million)
Figure 15. Global Anti-VEGF Drug Sales (2018-2029) & (K Units)
Figure 16. Global Anti-VEGF Drug Average Price (US$/Unit) & (2018-2029)
Figure 17. Anti-VEGF Drug Report Years Considered
Figure 18. Anti-VEGF Drug Sales Share by Manufacturers in 2022
Figure 19. Global Anti-VEGF Drug Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Anti-VEGF Drug Players: Market Share by Revenue in 2022
Figure 21. Anti-VEGF Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global Anti-VEGF Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 23. North America Anti-VEGF Drug Sales Market Share by Country (2018-2029)
Figure 24. North America Anti-VEGF Drug Revenue Market Share by Country (2018-2029)
Figure 25. United States Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Canada Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Europe Anti-VEGF Drug Sales Market Share by Country (2018-2029)
Figure 28. Europe Anti-VEGF Drug Revenue Market Share by Country (2018-2029)
Figure 29. Germany Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. France Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. U.K. Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Italy Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Russia Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Asia Pacific Anti-VEGF Drug Sales Market Share by Region (2018-2029)
Figure 35. Asia Pacific Anti-VEGF Drug Revenue Market Share by Region (2018-2029)
Figure 36. China Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Japan Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. South Korea Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. India Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Australia Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. China Taiwan Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Southeast Asia Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Latin America Anti-VEGF Drug Sales Market Share by Country (2018-2029)
Figure 44. Latin America Anti-VEGF Drug Revenue Market Share by Country (2018-2029)
Figure 45. Mexico Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Brazil Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Argentina Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Middle East & Africa Anti-VEGF Drug Sales Market Share by Country (2018-2029)
Figure 49. Middle East & Africa Anti-VEGF Drug Revenue Market Share by Country (2018-2029)
Figure 50. Turkey Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Saudi Arabia Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. UAE Anti-VEGF Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Global Sales Market Share of Anti-VEGF Drug by Type (2018-2029)
Figure 54. Global Revenue Market Share of Anti-VEGF Drug by Type (2018-2029)
Figure 55. Global Anti-VEGF Drug Price (US$/Unit) by Type (2018-2029)
Figure 56. Global Sales Market Share of Anti-VEGF Drug by Application (2018-2029)
Figure 57. Global Revenue Market Share of Anti-VEGF Drug by Application (2018-2029)
Figure 58. Global Anti-VEGF Drug Price (US$/Unit) by Application (2018-2029)
Figure 59. Anti-VEGF Drug Value Chain
Figure 60. Anti-VEGF Drug Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries